- Conditions
- Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, BMN 673
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 6
- States / cities
- Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 1,625
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Lymphomas, Bone Marrow Failure, Hemoglobinopathy, Immune Deficiency, Osteopetrosis
- Interventions
- CliniMACS® (T cell depletion)
- Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Head and Neck Neoplasms, Fibrosis, Lymphedema, Biomarkers, Polymorphism, Genetic, Depression
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
- Interventions
- tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
- Conditions
- Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
- Interventions
- Telemedicine, Genetic Testing, Internet-Based Intervention, Educational Intervention, Patient Navigation, Interview, Survey Administration
- Other · Behavioral
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 327
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 238 more
- Conditions
- Infections
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 20 Years to 74 Years · Female only
- Enrollment
- 3,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2044
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Tuberous Sclerosis
- Interventions
- Parent-Child Interaction Therapy (PCIT)
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 3 Years to 6 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Testicular Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 77 Years
- Enrollment
- 749 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Cancer
- Interventions
- dactinomycin, filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Colon Cancer
- Interventions
- Interview
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatocellular Carcinoma
- Interventions
- None - Standard of Care
- Other
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cancer Gene Mutation, Lynch Syndrome, Endometrial Cancer, Somatic Mutation
- Interventions
- Mismatch repair instability somatic and germline testing
- Diagnostic Test
- Lead sponsor
- RWJ Barnabas Health at Jersey City Medical Center
- Other
- Eligibility
- Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Jersey City, New Jersey
- Conditions
- Neoplasm
- Interventions
- Crizotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • St. Petersburg, Florida • Atlanta, Georgia + 9 more
- Conditions
- Primary Hyperparathyroidism, Parathyroid Cancer, Multiple Endocrine Neoplasias, Heritable Hyperparathyroidism, Hyperparathyroid-jaw Tumor Syndrome
- Interventions
- 18F-FCH, NeuroEXPLORER
- Drug · Device
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Capivasertib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma, Mismatch Repair Deficiency, Recurrent Endometrial Cancer, Metastatic Endometrial Cancer
- Interventions
- Biopsy, Carboplatin, Paclitaxel, Tislelizumab
- Procedure · Drug · Biological
- Lead sponsor
- Floor Backes, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Basal Cell Nevus Syndrome
- Interventions
- Levulan, Red Light PDT, Blue Light PDT
- Drug · Other
- Lead sponsor
- Edward Maytin, MD, PhD
- Other
- Eligibility
- Not listed
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- TSC1, TSC2, Tuberous Sclerosis Complex, MTOR
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Afatinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- RAD001, Placebo
- Drug
- Lead sponsor
- Mustafa Sahin
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Cincinnati, Ohio
- Conditions
- Genetic Predisposition
- Interventions
- Population-level screening
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 20,184 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Billings, Montana • Tacoma, Washington
- Conditions
- Haematologic Neoplasms
- Interventions
- AZD2962
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Miami, Florida • Tampa, Florida • Houston, Texas
- Conditions
- Tuberous Sclerosis Complex, Epilepsy
- Interventions
- Sirolimus, Placebo
- Drug
- Lead sponsor
- Darcy Krueger
- Other
- Eligibility
- 1 Day to 6 Months
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 5 more